<html><body><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5525">international conference</a></span> on harmonisation of technical requirements for registration of pharmaceuticals for human use   ich harmonised tripartite <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>  impurities in new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> q3b(r2)   current step 4 version dated 2 june 2006          this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> has been developed by the appropriate ich expert <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4543">working</a></span> group and has been subject to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532">consultation</a></span> by the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> parties, in accordance with the ich process.  at step 4 of the process the final draft is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> for adoption to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> bodies of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/665"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/909"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4054"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4060">european</a></span></a></span></a></span> union</a></span>, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1524">japan</a></span> and usa.   q3b(r2) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/486"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/494">document</a></span></a></span> history  first codification history date new codification november 2005 q3b <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> by the steering committee under step 2 and release for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2859">public</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532">consultation</a></span>. 29 november 1995 q3b q3b <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> by the steering committee under step 4 and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommendation</a></span> for adoption to the three ich <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> bodies. 6 november 1996 q3b q3b(r) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> by the steering committee of the first revision under step 2 and release for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2859">public</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532">consultation</a></span>. 7 october 1999 q3b(r1) q3b(r) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> by the steering committee of the first revision 
under step 4 and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommendation</a></span> for adoption to the three ich <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> bodies. 5 february 2003 q3b(r1) current step 4 version q3b(r2) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> by the steering committee of the revision of the 
attachment 2 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/448">directly</a></span> under step 4 without further <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2859">public</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532">consultation</a></span>. 2 june 2006 q3b(r2)    impurities in new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> ich harmonised tripartite <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> having reached step 4 of the ich process at the ich steering committee meeting  on 5 february 2003, this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> for  adoption to the three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> parties to ich attachment 2 has been revised on 6 june 2006.  table of contents 1. introduction........................................................................................1 1.1 objective of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>..........................................................................................1 1.2 background.................................................................................................................1 1.3 scope of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>................................................................................................1 2. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">rationale</a></span> for the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reporting</a></span> and control of degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>...................................................................1 3. analytical procedures..................................................................2 4. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reporting</a></span> degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> content of 
batches.....................................................................................................2 5. listing of degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> in specifications..3 6. qualification of degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>...........................4 7. glossary...................................................................................................6 attachment 1:  thresholds for degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> in new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>.....................7 attachment 2: illustration of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reporting</a></span> degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> results for identification and qualification in an application........................................................................................9 attachment 3:  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/348">decision</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2404">tree</a></span> for identification and qualification of a degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>...................................................................................................................................11   i impurities in new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>  1. introduction 1.1 objective of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/486"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/494">document</a></span></a></span> provides <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guidance</a></span> for registration applications on the content and qualification of impurities in new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> produced from chemically synthesised new drug substances not previously registered in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3031"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3096">region</a></span></a></span> or member <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">state</a></span>.  1.2 background this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> is complementary to the ich q3a(r) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> ﬁimpurities in new drug substancesﬂ, which should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5535">consulted</a></span></a></span> for basic principles.  the ich q3c <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> ﬁresidual <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solventsﬂ</a></span> should also be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5535">consulted</a></span></a></span>, if appropriate.  1.3 scope of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> addresses only those impurities in new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6004">classified</a></span> as degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> of the drug substance or reaction <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> of the drug substance with an excipient and/or immediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system (<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6032">collectively</a></span> referred to as ﬁdegradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">productsﬂ</a></span></a></span> in this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>). generally, impurities present in the new 
drug substance need not be monitored or specified in the new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> unless they are also degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> (see ich q6a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> on specifications). impurities arising from excipients present in the new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> or extracted or leached from the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system are not covered by this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>. this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> also does not apply to new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> used during the clinical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2914">research</a></span> stages of development. the following types of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> are not covered in this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span>/<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3797">biotechnological</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>, peptides, oligonucleotides, radiopharmaceuticals, fermentation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> and semi-synthetic <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> derived therefrom, herbal <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>, and crude <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> of animal or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/7379">plant</a></span> origin. also excluded from this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/486"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/494">document</a></span></a></span> are: (1) extraneous contaminants that should not occur in new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> and are more appropriately addressed as good manufacturing practice (gmp) issues, (2) polymorphic <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span>, and (3) enantiomeric impurities.  2. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">rationale</a></span> for the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reporting</a></span> and control of degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> the applicant should <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/78">summarise</a></span> the degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> during manufacture and/or stability studies of the new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>. this summary should be based on sound scientific appraisal of potential degradation pathways in the new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> and impurities arising from the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6908">interaction</a></span> with excipients and/or the immediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system. in addition, the applicant should <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/78">summarise</a></span> any laboratory studies conducted to detect degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> in the new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>. this summary should also include <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> results of batches manufactured during the 
development process and batches representative of the proposed commercial process. a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">rationale</a></span> should be provided for exclusion of those impurities that are not degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> (e.g., process impurities from the drug substance and impurities arising from excipients). the impurity profiles of the batches representative of the proposed commercial process should be compared with the profiles of batches used in development and any differences discussed.  any degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> in stability studies conducted at the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition should be identified when present at a level greater than (>) the 1 impurities in new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>  2 identification thresholds given in attachment 1. when identification of a degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> is not feasible, a summary of the laboratory studies demonstrating the unsuccessful efforts to identify it should be included in the registration application.  degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> present at a level of not more than () the identification threshold generally would not need to be identified. however, analytical procedures should be developed for those degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> that are suspected to be unusually potent, producing toxic or significant <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2367">pharmacological</a></span> effects at levels not more than () the identification threshold. in unusual circumstances, technical factors (e.g., manufacturing capability, a low drug substance to excipient <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">ratio</a></span>, or the use of excipients that are crude <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> of animal or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/7379">plant</a></span> origin) can be considered as part of the justification for selection of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> thresholds based upon manufacturing experience with the proposed commercial process. 3. analytical procedures the registration application should include <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/486"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/494">documented</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4434">evidence</a></span> that the analytical 
procedures have been validated and are suitable for the detection and quantitation of degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> (see ich q2a and q2b guidelines on analytical validation).  in particular, analytical procedures should be validated to demonstrate specificity for the specified and unspecified degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>. as appropriate, this validation should include <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> stored under relevant stress conditions: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span>, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5503">heat</a></span>, humidity, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5035">acid</a></span>/base hydrolysis, and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2213">oxidation</a></span>. when an analytical procedure reveals the presence of other peaks in addition to those of the degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> (e.g., the drug substance, impurities arising from the synthesis of the drug substance, excipients and impurities arising from the excipients), these peaks should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labeled</a></span> in the 
chromatograms and their origin(s) discussed in the validation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/486"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/494">documentation</a></span></a></span>.   the quantitation limit for the analytical procedure should be not more than () the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reporting</a></span> threshold. degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> levels can be measured by a variety of techniques, including those that compare an analytical response for a degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> to that of an appropriate reference <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2077">standard</a></span> or to the response of the new drug substance itself. reference <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2077">standards</a></span> used in the analytical procedures for control of degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> should be evaluated and characterised according to their intended uses. the 
drug substance can be used to estimate the levels of degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>. in cases where the response factors are not close, this practice can still be used if a correction factor is applied or the degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> are, in fact, being overestimated. acceptance criteria and analytical procedures, used to estimate identified or unidentified degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>, are often based on analytical assumptions (e.g., equivalent detector response). these assumptions should be discussed in the 
registration application. differences between the analytical procedures used during development and those proposed for the commercial <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> should also be discussed. 4. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reporting</a></span> degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> content of batches analytical results should be provided in the registration application for all relevant batches of the new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> used for clinical, safety, and stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>, as well as batches that are representative of the proposed commercial process. quantitative results should be presented numerically, and not in general terms such as ﬁcompliesﬂ, ﬁmeets limitﬂ etc. any degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> at a level greater than (>) the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reporting</a></span> impurities in new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>  3 threshold (see attachment 1), and total degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> in the relevant batches of the new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>, should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reported</a></span> with the analytical procedures indicated.  below 1.0%, the results should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reported</a></span> to the number of decimal places (e.g., 0.06%) in the applicable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reporting</a></span> threshold; at and above 1.0%, the results should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reported</a></span> to one decimal place (e.g., 1.3%).  results should be rounded using conventional <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1538">rules</a></span> (see attachment 2).  a tabulation (e.g., <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5924">spreadsheet</a></span>) of the data is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span>.  degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> should be designated by <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6019">code</a></span> number or by an appropriate descriptor, e.g., retention time.  if a higher <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reporting</a></span> threshold is 
proposed, it should be fully justified. all degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> at a level greater than (>) the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reporting</a></span> threshold should be summed and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reported</a></span> as total degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>.   chromatograms with peaks <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labelled</a></span> (or equivalent data if other analytical procedures are used) from representative batches, including chromatograms from analytical procedure validation studies and from long-term and accelerated stability studies, should be provided. the applicant should ensure that complete degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> profiles (e.g., chromatograms) of individual batches are available, if requested.  for each batch of the new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> described in the registration application, the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/486"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/494">documentation</a></span></a></span> should include:  batch identity, strength, and size  date of manufacture  site of manufacture  manufacturing process  immediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure   degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> content, individual and total  use of batch (e.g., clinical studies, stability studies)   reference to analytical procedure used  batch number of the drug substance used in the new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions for stability studies 5. listing of degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> in specifications the specification for a new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> should include a list of degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 
expected to occur during manufacture of the commercial <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> and under <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions. stability studies, knowledge of degradation pathways, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> development studies, and laboratory studies should be used to characterise the degradation profile.  the selection of degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> in the new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> specification should be based on the degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> found in batches manufactured by the proposed commercial process. those individual 
degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> with specific acceptance criteria included in the specification for the new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> are referred to as "specified degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>" in this 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>. specified degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> can be identified or unidentified.  a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">rationale</a></span> for the inclusion or exclusion of degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> in the specification should be presented. this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">rationale</a></span> should include a discussion of the degradation 
profiles <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> in the safety and clinical development batches and in stability 
studies, together with a consideration of the degradation profile of batches manufactured by the proposed commercial process. specified identified degradation impurities in new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>  4 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> should be included along with specified unidentified degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> estimated to be present at a level greater than (>) the identification threshold given in attachment 1. for degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> known to be unusually potent or to produce toxic or unexpected <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2367">pharmacological</a></span> effects, the quantitation/detection limit of the analytical procedures should be commensurate with the level at which the 
degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> should be controlled. for unidentified degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>, the procedure used and assumptions made in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establishing</a></span> the level of the degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> should be clearly <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">stated</a></span>.  specified unidentified degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> should be referred to by an appropriate qualitative analytical descriptive <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> (e.g., ﬁunidentified a", ﬁunidentified with relative retention of 0.9ﬂ). a general acceptance criterion of not more than () the identification threshold (attachment 1) for any unspecified degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> and an acceptance criterion for total degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> should also be included. for a given degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>, its acceptance criterion should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">established</a></span> by taking into <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/54"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/60"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/61">account</a></span></a></span></a></span> its acceptance criterion in the drug substance (if applicable), its qualified level, its increase during stability studies, and the proposed shelf life and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions for the new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>.   furthermore, each acceptance criterion should be set no higher than the qualified level of the given degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>.   where there is no safety concern, degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> acceptance criteria should be based on data generated from batches of the new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> manufactured by the 
proposed commercial process, allowing sufficient latitude to deal with normal 
manufacturing and analytical variation and the stability characteristics of the new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>. although normal manufacturing variations are expected, significant variation in batch-to-batch degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> levels can indicate that the manufacturing process of the new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> is not adequately controlled and validated (see ich q6a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> on specifications, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/348">decision</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2404">tree</a></span> #2, for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establishing</a></span> an acceptance criterion for a specified degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> in a new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>).  in this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>, the use of two decimal places for thresholds (see attachment 1) does 
not necessarily indicate the precision of the acceptance criteria for specified 
degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> and total degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>. in summary, the new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> specification should include, where applicable, the following list of degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>:  each specified identified degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>  each specified unidentified degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>   any unspecified degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> with an acceptance criterion of not more than () the identification threshold  total degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>. 6. qualification of degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> qualification is the process of acquiring and evaluating data that <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establishes</a></span> the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span> safety of an individual degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> or a given degradation profile at the level(s) specified. the applicant should provide a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">rationale</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establishing</a></span> 
degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> acceptance criteria that includes safety considerations. the level of any degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> present in a new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> that has been adequately <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> in safety and/or clinical studies would be considered qualified. therefore, it is useful to include any available <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> on the actual content of degradation impurities in new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>  5 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> in the relevant batches at the time of use in safety and/or clinical studies.  degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> that are also significant metabolites present in animal and/or human studies are generally considered qualified.  degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> could be considered qualified at levels higher than those administered in safety studies based on a comparison between actual doses given in the safety studies and the intended dose of the new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>. justification of such higher levels should include consideration of factors such as: (1) the amount of degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> administered in previous safety and/or clinical studies and found to be safe; (2) the increase in the amount of the degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>; and (3) other safety factors, as appropriate.   if the qualification thresholds given in attachment 1 are exceeded and data are unavailable to qualify the proposed acceptance criterion of a degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>, additional studies to obtain such data can be appropriate (see attachment 3).  higher or lower thresholds for qualification of degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> can be 
appropriate for some individual new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> based on scientific <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">rationale</a></span> and level of concern, including drug class effects and clinical experience. for example, qualification can be especially <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1309">important</a></span> when there is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4434">evidence</a></span> that such degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> in certain new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4455">therapeutic</a></span> classes have 
previously been <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2944">associated</a></span> with adverse reactions in patients. in these instances, a lower qualification threshold can be appropriate. conversely, a higher qualification threshold can be appropriate for individual new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> when the level of concern for safety is less than usual based on similar considerations (e.g., patient <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/7413">population</a></span>, drug class effects, and clinical considerations).  proposals for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> thresholds would be considered on a case-by-case basis. the "<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/348">decision</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2404">tree</a></span> for identification and qualification of a degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>" (attachment 3) describes considerations for the qualification of degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> when thresholds are exceeded.  in some cases, reducing the level of degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> (e.g., use of a more protective <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure or modified <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions) to not more than () the threshold can be simpler than providing safety data.  alternatively, adequate data could be available in the scientific <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1680">literature</a></span> to qualify a degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>. if neither is the case, additional safety <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should be considered. the studies considered appropriate to qualify a degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> will <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5390">depend</a></span> on a number of factors, including the patient <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/7413">population</a></span>, daily dose, and 
route and duration of new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/8542">administration</a></span>. such studies can be conducted on the new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> or substance <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containing</a></span> the degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> to be controlled, although studies using <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1510">isolated</a></span> degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> can sometimes be appropriate. although this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> is not intended to apply during the clinical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2914">research</a></span> stage of development, in the later stages of development the thresholds in this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> can be useful in evaluating new degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> in new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> batches prepared by the proposed commercial process.  any new degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> in later stages of development should be identified (see the ﬁdecision <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2404">tree</a></span> for identification and qualification of a degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">productﬂ</a></span></a></span> in attachment 3) if its level is greater than (>) the identification threshold given in attachment 1. similarly, qualification of the degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> should be considered if its level is greater than (>) the qualification threshold given in attachment 1.  safety studies should provide a comparison of results of safety <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of the new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> or drug substance <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containing</a></span> a representative level of the degradation impurities in new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>  6 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> with previously qualified material, although studies using the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1510">isolated</a></span> degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> can also be considered. 7. glossary degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>: an impurity resulting from a chemical change in the drug substance brought about during manufacture and/or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> of the new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> by the effect of, for example, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span>, temperature, ph, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span>, or by reaction with an excipient and/or the immediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system. degradation profile: a description of the degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> in the drug substance or drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>. development studies: studies conducted to scale-up, optimise, and validate the manufacturing process for a drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>. identification threshold: a limit above (>) which a degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> should be identified. identified degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>: a degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> for which a structural characterisation has been achieved. impurity:  any component of the new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> that is not the drug substance or an excipient in the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>.  impurity profile: a description of the identified and unidentified impurities present in a drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>. new drug substance:  the designated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4455">therapeutic</a></span> moiety that has not been previously registered in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3031"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3096">region</a></span></a></span> or member <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">state</a></span> (also referred to as a new molecular entity or new chemical entity).  it can be a complex, simple ester, or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3758">salt</a></span> of a previously <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approved</a></span> substance. qualification:  the process of acquiring and evaluating data that <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establishes</a></span> the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span> safety of an individual degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> or a given degradation profile at the level(s) specified. qualification threshold: a limit above (>) which a degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> should be qualified. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reporting</a></span> threshold: a limit above (>) which a degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reported</a></span>. specified degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>: a degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> that is individually listed and limited with a specific acceptance criterion in the new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> specification. a specified degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> can be either identified or unidentified. unidentified degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>: a degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> for which a structural characterisation has not been achieved and that is defined solely by qualitative analytical properties (e.g., chromatographic retention time). unspecified degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>: a degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> that is limited by a general acceptance criterion, but not individually listed with its own specific acceptance criterion, in the new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> specification. impurities in new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>  7 attachment 1:  thresholds for degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> in new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reporting</a></span> thresholds maximum daily dose1threshold2,3 1  g 0.1% > 1 g 0.05%  identification thresholds maximum daily dose1threshold2, 3< 1 mg 1.0% or 5 µg tdi, whichever is lower 1 mg - 10 mg 0.5% or 20 µg tdi, whichever is lower >10 mg - 2 g 0.2% or 2 mg tdi, whichever is lower >  2 g 0.10%  qualification thresholds maximum daily dose1threshold2,3< 10 mg 1.0% or 50 µg tdi, whichever is lower 10 mg - 100 mg 0.5% or 200 µg tdi, whichever is lower >100 mg - 2 g 0.2% or 3 mg tdi, whichever is lower > 2 g 0.15%  notes on attachment 1 1 the amount of drug substance administered per day 2 thresholds for degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> are expressed either as a percentage of the drug substance or as total daily intake (tdi) of the degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>.  lower thresholds can be appropriate if the degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> is unusually toxic. 3 higher thresholds should be scientifically justified. impurities in new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>  illustration of thresholds for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reporting</a></span>, identification, and qualification of degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> in new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> as a function of  maximum daily dose1 0.000.200.400.60
0.801.0005001000150020002500maximum daily dose expressed in mg of drug substancepercentage of drug substancereportingidentificationqualificationexpanded scale: 0.000.20
0.40
0.60
0.80
1.0005101520maximum daily dose expressed in mg of drug substancepercentage of drug substancereportingidentificationqualification                                                 1 note : actual threshold values should be taken from the preceding table in this attachment. 8 impurities in new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>  9 attachment 2: illustration of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reporting</a></span> degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> results for identification and qualification in an application the attachment is only illustrative and is not intended to serve as a template how results on degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> should be presented in an application file. normally raw data are not provided. example 1: 50 mg maximum daily dose   <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reporting</a></span> threshold: 0.1%   identification threshold: 0.2%   qualification threshold: 200 g action 'raw' result  (%)   <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reported</a></span> result (%) (<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reporting</a></span> threshold = 0.1%)  total daily intake (tdi) of the degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> (rounded result in g)identification threshold 0.2% exceeded? qualification threshold 200 g tdi exceeded? 0.04 not <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reported</a></span> 20 none none 0.2143 0.2 100 none none 0.349 0.31150 yes none10.550 0.61300 yes yes1 example 2: 1.9 gram maximum daily dose   <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reporting</a></span> threshold: 0.05%   identification threshold: 2 mg   qualification threshold: 3 mg action 'raw' result  (%)   <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reported</a></span> result (%) (<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reporting</a></span> threshold = 0.05%) total daily intake (tdi) of the degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> (rounded result in mg) identification threshold 2 mg tdi exceeded? qualification threshold 3 mg tdi exceeded? 0.049 not <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reported</a></span> 1 none none 0.079 0.08 2 none none 0.183 0.1813 yes none1, 20.192 0.1914 yes yes1impurities in new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>  10 notes on attachment 2  1 after identification, if the response factor is determined to differ significantly from the original assumptions, it can be appropriate to re-measure the actual amount of the degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> present and re-evaluate against the qualification threshold (see attachment 1).  2 to verify if a threshold is exceeded, a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reported</a></span> result has to be evaluated against the thresholds as follows: when the threshold is described in %, the 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reported</a></span> result rounded to the same decimal place as the threshold should be compared <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/448">directly</a></span> to the threshold. when the threshold is described in tdi, the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reported</a></span> result should be converted to tdi, rounded to the same decimal place as the threshold and compared to the threshold e.g. an amount of 0.18% degradation level <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/242">corresponds</a></span> to a tdi of 3.4 mg impurity (absolute amount) which is then rounded down to 3 mg; so the qualification threshold expressed in tdi (3 mg) is not exceeded. impurities in new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>  attachment 3:  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/348">decision</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2404">tree</a></span> for identification and qualification of a degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> is degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> greater than identification thresholdc?  qualified reduce to safe level yes anyclinically relevant adverse effects? no no action yes no consider patient <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/7413">population</a></span> and duration of use and consider conducting:  genotoxicity studies (point mutation, chromosomal aberration)a  general toxicity studies (one species, usually  14 to 90 days)b  other specific toxicity endpoints, as appropriate yes structure identified? no greaterthan qualification thresholdc? yes no further action reduceto not more than () qualification thresholdc? yes reduce to not more than () identification thresholdc? no anyknown human relevant risksd? yes no no action reduce to safe level yes no no 11 impurities in new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>  12 notes on attachment 3 a) if considered desirable, a minimum <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5601">screen</a></span> (e.g., genotoxic potential), should be conducted. a study to detect point mutations and one to detect chromosomal aberrations, both in vitro, are considered an appropriate minimum <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5601">screen</a></span>. b) if general toxicity studies are desirable, one or more studies should be designed to allow comparison of unqualified to qualified material.  the study duration should be based on available relevant <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> and performed in the species most likely to maximise the potential to detect the toxicity of a degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>. on a case-by-case basis, single-dose studies can be appropriate, especially for single-dose drugs. in general, a minimum duration of 14 days and a maximum duration of 90 days would be considered appropriate. c) lower thresholds can be appropriate if the degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> is unusually toxic. d) for example, do known safety data for this degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> or its structural class preclude human exposure at the concentration present? </body><html>